Revance Therapeutics (RVNC) Reports Publication of SAKURA 1 & SAKURA 2 Results in Plastic and Reconstructive Surgery

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. PANW
3. CL
4. SNDK
5. TAP
6. DELL
7. ROIV
8. ANET
9. NKE
10. BE

Go back to Revance Therapeutics (RVNC) Reports Publication of SAKURA 1 & SAKURA 2 Results in Plastic and Reconstructive Surgery

Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery

November 4, 2019 8:00 AM EST

- Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more -

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the publication of results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery (PRS), the peer reviewed Journal of the American Society of Plastic Surgeons. These two Phase 3 studies evaluated Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), for the... More